Patient info Open main menu

Sacubitril/valsartan Krka 49 mg/51 mg film-coated tablets – patient leaflet, side effects, dosage

Last updated: · Text from the MHRA, as of · About this document

Medicine status: Prescription only (POM) Details

Medicine strength:
49 mg/51 mg
Contains active substances:

Patient leaflet - Sacubitril/valsartan Krka 49 mg/51 mg film-coated tablets

1. What Sacubitril/Valsartan Krka is and what it is used for

Sacubitril/Valsartan Krka is a heart medicine containing an angiotensin receptor neprilysin inhibitor. It delivers two active substances, sacubitril and valsartan.

Sacubitril/Valsartan Krka is used to treat a type of long-term heart failure in adults, children and adolescents (one year and older).

This type of heart failure occurs when the heart is weak and cannot pump enough blood to the lungs and the rest of the body. The most common symptoms of heart failure are breathlessness, fatigue, tiredness and ankle swelling.

2. What you need to know before you take Sacubitril/Valsartan Krka

Do not take Sacubitril/Valsartan Krka

  • if you are allergic to sacubitril, valsartan or any of the other ingredients of this medicine (listed in section 6).
  • if you are taking another type of medicine called an angiotensin converting enzyme (ACE) inhibitor (for example enalapril, lisinopril or ramipril), which is used to

    treat high blood pressure or heart failure. If you have been taking an ACE inhibitor, wait for 36 hours after taking the last dose before you start to take Sacubitril/Valsartan Krka (see “Other medicines and Sacubitril/Valsartan Krka”).

    • if you have ever had a reaction called angioedema (rapid swelling under the skin in areas such as the face, throat, arms and legs which can be life threatening if throat swelling blocks the airway) when taking an ACE inhibitor or an angiotensin receptor blocker (ARB) (such as valsartan, telmisartan or irbesartan).
    • if you have a history of angioedema which is hereditary or for which the cause is unknown (idiopathic).
    • if you have diabetes or impaired kidney function and you are being treated with a blood pressure lowering medicine containing aliskiren (see “Other medicines and Sacubitril/Valsartan Krka”).
    • if you have severe liver disease.
    • if you are more than 3 months pregnant (see “Pregnancy and breast-feeding”).

If any of the above applies to you, do not take Sacubitril/Valsartan Krka and talk to your doctor. Warnings and precautions

Talk to your doctor, pharmacist or nurse before and when taking Sacubitril/Valsartan Krka.

  • if you are being treated with an angiotensin receptor blocker (ARB) or aliskiren (see “Do not take Sacubitril/ Valsartan Krka”).
  • if you have ever had angioedema (see “Do not take Sacubitril/Valsartan Krka” and section 4 “Possible side effects”).

    • if you experience abdominal pain, nausea, vomiting or diarrhoea after taking Sacubitril/Valsartan Krka. Your doctor will decide on further treatment. Do not stop taking Sacubitril/Valsartan Krka on your own.
    • if you have low blood pressure or are taking any other medicines that reduce your blood pressure (for example, a medicine that increases urine production (diuretic)) or are suffering from vomiting or diarrhoea, especially if you are aged 65 years or more, or if you have kidney disease and low blood pressure.
    • if you have kidney disease.
    • if you are suffering from dehydration.
    • if your kidney artery has narrowed.
    • if you have liver disease.
    • if you experience hallucinations, paranoia or changes in sleeping pattern while taking Sacubitril/Valsartan Krka.
    • if you have hyperkalaemia (high levels of potassium in the blood).
    • if you suffer from heart failure classified as NYHA class IV (unable to carry on any physical activity without discomfort and may have symptoms even when resting). If any of the above applies to you, tell your doctor, pharmacist or nurse before you take Sacubitril/ Valsartan Krka.

Your doctor may check the amount of potassium and sodium in your blood at regular intervals during Sacubitril/Valsartan Krka treatment. In addition, your doctor may check your blood pressure at start of treatment and when the doses are increased.

Children and adolescents

Do not give this medicine to children aged below 1 year because it has not been studied in this age group. This

medicine is not suitable for children aged one year and older with a body weight below 40 kg because it may not be possible to take the correct dose with Sacubitril/ Valsartan Krka tablets. Your doctor or pharmacist will check if there is a suitable alternative (granules) available, so that the correct dose can be taken.

Other medicines and Sacubitril/Valsartan Krka

Tell your doctor, pharmacist or nurse if you (or your child) are taking, have recently taken or might take any other medicines. It may be necessary to change the dose, to take other precautions, or even to stop taking one of the medicines. This is particularly important for the following medicines:

  • ACE inhibitors. Do not take Sacubitril/Valsartan Krka with ACE inhibitors. If you have been taking an ACE inhibitor, wait 36 hours after taking the last dose of the ACE inhibitor before starting to take Sacubitril/Valsartan Krka (see “Do not take Sacubitril/Valsartan Krka”). If you stop taking Sacubitril/Valsartan Krka, wait 36 hours after taking your last dose of Sacubitril/Valsartan Krka before starting an ACE inhibitor.
  • other medicines used to treat heart failure or lower blood pressure, such as angiotensin receptor blockers or aliskiren (see “Do not take Sacubitril/Valsartan Krka”).
  • some medicines known as statins that are used to lower high cholesterol levels (for example atorvastatin).
  • sildenafil, tadalafil, vardenafil or avanafil, which are medicines used to treat erectile dysfunction or lung hypertension.
  • medicines that increase the amount of potassium in the blood. These include potassium supplements, salt substitutes containing potassium, potassium-sparing medicines and heparin.

    • painkillers of the type called non-steroidal anti-inflammatory medicines (NSAIDs) or selective cyclooxygenase-2 (Cox-2) inhibitors. If you are taking one of these, your doctor may want to check your kidney function when starting or adjusting treatment (see “Warnings and precautions”).
    • lithium, a medicine used to treat some types of psychiatric illness.
    • furosemide, a medicine belonging to the type known as diuretics, which are used to increase the amount of urine you produce.
    • nitroglycerine, a medicine used to treat angina pectoris.
    • some types of antibiotics (rifamycin group), ciclosporin (used to prevent rejection of transplanted organs) or antivirals such as ritonavir (used to treat HIV/AIDS).
    • metformin, a medicine used to treat diabetes. If any of the above applies to you, tell your doctor or pharmacist before you take Sacubitril/Valsartan Krka. Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Pregnancy

You must tell your doctor if you think that you are (or might become) pregnant. Your doctor will normally advise you to stop taking this medicine before you become pregnant or as soon as you know you are pregnant, and will advise you to take another medicine instead of Sacubitril/Valsartan Krka. This medicine is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if it is used after the third month of pregnancy.

Breast-feeding

Sacubitril/Valsartan Krka is not recommended for mothers who are breast-feeding. Tell your doctor if you are breast-feeding or about to start breast-feeding.

Driving and using machines

Before you drive a vehicle, use tools or operate machines, or carry out other activities that require concentration, make sure you know how Sacubitril/Valsartan Krka affects you. If you feel dizzy or very tired while taking this medicine, do not drive a vehicle, cycle or use any tools or machines.

Sacubitril/Valsartan Krka contains sodium

This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodium free’.

3. How to take Sacubitril/Valsartan Krka

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

Adults

You will usually start by taking a 24 mg/26 mg or 49 mg/51 mg tablet twice a day (one tablet in the morning and one tablet in the evening). Your doctor will decide your exact starting dose based on which medicines you have been taking previously and your blood pressure. Your doctor will then adjust the dose every 2-4 weeks depending on how you respond to the treatment until the best dose for you is found.

The usual recommended target dose is 97 mg/103 mg twice a day (one tablet in the morning and one tablet in the evening).

MockUp031881_1

IDUF
I'll"

130 mm ± 0,5 mm smer branja kode/direction of reading PhC

smer branja kode/direction of reading PhC 130 mm ± 0,5 mm

smer vlaken/direction on fibre

PL.Sacubitril/Valsartan fct GB second page

Children and adolescents (one year and older) Your (or your child’s) doctor will decide the starting dose based on body weight and other factors including previously taken medicines. The doctor will adjust the dose every 2-4 weeks until the best dose is found. Sacubitril/Valsartan Krka should be given twice a day (one tablet in the morning and one tablet in the evening). Sacubitril/Valsartan Krka film-coated tablets are not meant to be used in children who weigh less than 40 kg. For these patients, your doctor or pharmacist will check if a suitable alternative (granules) is available.

Patients taking Sacubitril/Valsartan Krka can develop low blood pressure (dizziness, light-headedness), a high level of potassium in the blood (which would be detected when your doctor performed a blood test) or decreased kidney function. If this happens, your doctor may reduce the dose of any other medicine you are taking, temporarily reduce the Sacubitril/Valsartan Krka dose, or stop Sacubitril/ Valsartan Krka treatment completely.

Swallow the tablets with a glass of water. You can take Sacubitril/Valsartan Krka with or without food. Splitting or crushing of the tablets is not recommended. Sacubitril/ Valsartan Krka tablets are film-coated in order to be protected from environmental influences and to enable you to swallow the tablet with more ease. The coating is not suitable for crushing.

If you take more Sacubitril/Valsartan Krka than you should

If you have accidentally taken too many Sacubitril/ Valsartan Krka tablets, or if someone else has taken your tablets, contact your doctor immediately. If you experience

severe dizziness and/or fainting, tell your doctor as quickly as possible and lie down.

If you forget to take Sacubitril/Valsartan Krka

It is advisable to take your medicine at the same time each day. However, if you forget to take a dose, you should simply take the next one at the scheduled time. Do not take a double dose to make up for a forgotten dose. If you stop taking Sacubitril/Valsartan Krka

Stopping your treatment with Sacubitril/Valsartan Krka may cause your condition to get worse. Do not stop taking your medicine unless your doctor tells you to.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Some side effects may be serious.

  • Stop taking Sacubitril/Valsartan Krka and seek immediate medical attention if you notice any swelling of the face, lips, tongue and/or throat, which may cause difficulties in breathing or swallowing. These may be signs of angioedema (an uncommon side effect which may affect up to 1 in 100 people).
  • Intestinal angioedema: a swelling in the gut presenting with symptoms like abdominal pain, nausea, vomiting and diarrhoea (a very rare side effect which may affect up to 1 in 10 000 people).

Other possible side effects:

If any of the side effects listed below becomes severe, tell your doctor or pharmacist.

Very common (may affect more than 1 in 10 people)

  • low blood pressure, which can cause symptoms of dizziness and light-headedness (hypotension)
  • high level of potassium in the blood, shown in a blood test (hyperkalaemia)
  • decreased kidney function (renal impairment) Common (may affect up to 1 in 10 people)
  • cough
  • dizziness
  • diarrhoea
  • low level of red blood cells, shown in a blood test (anaemia)
  • tiredness (fatigue)
  • (acute) inability of the kidney to work properly (renal failure)
  • low level of potassium in the blood, shown in a blood test (hypokalaemia)
  • headache
  • fainting (syncope)
  • weakness (asthenia)
  • feeling sick (nausea)
  • low blood pressure (dizziness, light-headedness) when switching from sitting or lying to standing position
  • gastritis (stomach pain, nausea)
  • spinning sensation (vertigo)
  • low level of sugar in the blood, shown in a blood test (hypoglycaemia)

Uncommon (may affect up to 1 in 100 people)

  • allergic reaction with rash and itching (hypersensitivity)
  • dizziness when switching from sitting to standing position (dizziness postural)

    • low level of sodium in the blood, shown in a blood test (hyponatraemia)

Rare (may affect up to 1 in 1 000 people)

  • seeing, hearing or feeling things that are not there (hallucinations)
  • changes in sleeping pattern (sleep disorder) Very rare (may affect up to 1 in 10 000 people)
  • paranoia

Not known (frequency cannot be estimated from the available data)

  • sudden involuntary muscle twitching (myoclonus). Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme Website:

www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Sacubitril/Valsartan Krka

Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton and blister after ‘EXP’. The expiry date refers to the last day of that month.

This medicine does not require any special temperature storage conditions.

Store in the original package in order to protect from moisture.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Sacubitril/Valsartan Krka contains

  • The active substances are sacubitril and valsartan. Sacubitril/Valsartan Krka 24 mg/26 mg film-coated tablets

    Each film-coated tablet contains sacubitril sodium equivalent to 24.3 mg sacubitril and valsartan disodium equivalent to 25.7 mg valsartan.

    Sacubitril/Valsartan Krka 49 mg/51 mg film-coated tablets

    Each film-coated tablet contains sacubitril sodium equivalent to 48.6 mg sacubitril and valsartan disodium equivalent to 51.4 mg valsartan.

    Sacubitril/Valsartan Krka 97 mg/103 mg film-coated tablets

    Each film-coated tablet contains sacubitril sodium equivalent to 97.2 mg sacubitril and valsartan disodium equivalent to 102.8 mg valsartan.

  • The other ingredients in the tablet core are povidone, microcrystalline cellulose, talc, crospovidone, colloidal anhydrous silica and magnesium stearate.
  • The other ingredients in the film coating are coating mixture (poly(vinyl alcohol), calcium carbonate, macrogol and talc), red iron oxide (E172) [only for 24 mg/26 mg and 97 mg/103 mg], black iron oxide (E172) [only for

    24 mg/26 mg] and yellow iron oxide (E172) [only for 49 mg/51 mg].

    See section 2 “Sacubitril/Valsartan Krka contains sodium”.

    What Sacubitril/Valsartan Krka looks like and contents of the pack

    Sacubitril/Valsartan Krka 24 mg/26 mg film-coated tablets Light greyish pink, round, biconvex, film-coated tablet, marked with S3 on one side. Tablet dimension: diameter approx. 9 mm

    Sacubitril/Valsartan Krka 49 mg/51 mg film-coated tablets Yellow, round, biconvex, film-coated tablet, marked with S2 on one side. Tablet dimension: diameter approx. 9 mm Sacubitril/Valsartan Krka 97 mg/103 mg film-coated tablets Orangish pink, oval, biconvex, film-coated tablet, marked with S1 on one side. Tablet dimension: approx. 15 mm x 8 mm

    Sacubitril/Valsartan Krka is available in packs containing

    • 14, 20, 28, 56, 60, 168, 196 and 200 film-coated tablets, in blisters.
    • 14, 28, 56, 168 and 196 film-coated tablets, in blisters, calendar pack.

Not all pack sizes may be marketed.

Marketing Authorisation Holder and Manufacturer

KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia

This leaflet was last revised in 01/2026.

MockUp031881_1

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PL 01656/0485

Last revision stated in the text: January 2026 · MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Sacubitril/valsartan Krka 49 mg/51 mg film-coated tablets

Prescription needed? Yes, prescription-only medicine (POM)
Active substances Valsartan, Sacubitril
Strength 49 mg/51 mg
Pharmaceutical form Oral tablet
Yellow, round, biconvex, film-coated tablet, marked with S2 on one side. Tablet dimension: diameter approx. 9 mm
How is it taken Oral
Excipients Povidone, Cellulose, microcrystalline, Talc, Crospovidone, Silica, colloidal anhydrous, Magnesium stearate, poly(vinyl alcohol), calcium carbonate, macrogol, talc, Iron oxide, yellow (E172)
Is it available? Listed as available (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Shelf life 3 years
Storage This medicinal product does not require any special temperature storage conditions.
Store in the original package in order to protect from moisture.
Drug group (ATC) Agents acting on the renin-angiotensin system, angiotensin II receptor blockers (ARBs), other combinations
  1. C Cardiovascular system drugs
    1. C09 Agents acting on the renin-angiotensin system
      1. C09D Angiotensin II receptor blockers (ARBs), combinations
        1. C09DX Angiotensin II receptor blockers (ARBs), other combinations
          1. C09DX04 valsartan and sacubitril
Marketing authorisation PL 01656/0485 (first authorised 10 June 2026)
Marketing authorisation holder KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
Codes BNF 02050502

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 10.1.0 of 12 October 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.